The National Institute for Health and Care Excellence (NICE) has opted not to recommend Biogen’s Fampyra (fampridine) in England as part of updated guidelines for the diagnosis and management of multiple sclerosis (MS). 22 June 2022
An immuno-oncology focused startup in India is initiating a Phase II trial of its lead candidate, after a successful series A financing raised $15 million. 21 June 2022
AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor to treat moderately to severely active Crohn's disease (CD). 17 June 2022
The US Food and Drug Administration today authorized emergency use of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine for the prevention of COVID-19 to include use in children down to six months of age, with the decision coming just a day after an FDA advisory panel recommended approval in this age group. 17 June 2022
Today Everest Medicines announced the approval of its New Drug Application (NDA) for Trodelvy (sacituzumab govitecan) from China’s National Medical Products Administration (NMPA) to treat adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. 10 June 2022
Swiss cancer giant Roche has secured the first and only European approval for a checkpoint blocker in a subset of people with early-stage non-small cell lung cancer (NSCLC). 9 June 2022
On Saturday, Bristol Myers Squibb announced that it has withdrawn a supplemental biologics license application (sBLA) for Reblozyl (luspatercept-aamt) for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia. 4 June 2022
California, USA-based Catalyst Biosciences has signed a definitive asset purchase and sale agreement with Vertex Pharmaceuticals, under which Vertex has acquired Catalyst’s portfolio of protease medicines that regulate complement, including CB 2782-PEG, for $60 million in cash. 27 May 2022
The CD19 targeted CAR-T therapy Yescarta (axicabtagene ciloleucel) was added in the Shanghai local government-backed commercial health insurance scheme Hu Hui Bao. 25 May 2022
In Europe, AstraZeneca's COVID-19 vaccine, Vaxzevria, has been granted approval as a third dose booster in adults, including for those who had mRNA-based jabs initially. 23 May 2022
Finnish drug delivery firm DelSiTech has joined forces with a precision medicine firm based in China, Anticancer Bioscience, to develop silica-based therapies in oncology. 18 May 2022
Gilead Sciences is to put forward more than 20 abstracts, including two oral presentations and four poster discussions, at the annual congress of the American Society of Clinical Oncology (ASCO 22). 18 May 2022
French pharma major Sanofi has raised the curtain on data to be shared at the upcoming American Society of Clinical Oncology (ASCO 22) meeting. 17 May 2022
US messenger RNA (mRNA) therapeutics and vaccines specialist Moderna yesterday announced that its recently appointed chief financial officer, Jorge Gomez, has departed the company, effective immediately. 12 May 2022
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024